Literature DB >> 17688287

Epigenetic "bivalently marked" process of cancer stem cell-driven tumorigenesis.

Curt Balch1, Kenneth P Nephew, Tim H-M Huang, Sharmila A Bapat.   

Abstract

Silencing of tumor suppressor genes (TSGs), by DNA methylation, is well known in adult cancers. However, based on the "stem cell" theory of tumorigenesis, the early epigenetic events arising in malignant precursors remain unknown. A recent report demonstrates that, while pluripotent embryonic stem cells lack DNA methylation and possess a "bivalent" pattern of activating and repressive histone marks in numerous TSGs, analogous multipotent malignant cells derived from germ cell tumors (embryonic carcinoma cells) gain additional silencing modifications to those same genes. These results suggest a possible mechanism by which aberrant differentiation, mediated by histone and DNA methylation, instigates tumor progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17688287     DOI: 10.1002/bies.20619

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  17 in total

1.  Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells.

Authors:  Sharmila A Bapat; Victor Jin; Nicholas Berry; Curt Balch; Neeti Sharma; Nawneet Kurrey; Shu Zhang; Fang Fang; Xun Lan; Meng Li; Brian Kennedy; Robert M Bigsby; Tim H M Huang; Kenneth P Nephew
Journal:  Epigenetics       Date:  2010-11-01       Impact factor: 4.528

2.  Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers.

Authors:  You-Kyung Jeon; Sung-Hee Kim; Seung-Ho Choi; Kyung-Hee Kim; Byong-Chul Yoo; Ja-Lok Ku; Jae-Gahb Park
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

3.  CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma.

Authors:  Walter Henriques da Costa; Rafael Malagoli Rocha; Isabela Werneck da Cunha; Francisco Paula da Fonseca; Gustavo Cardoso Guimaraes; Stenio de Cassio Zequi
Journal:  World J Urol       Date:  2011-10-04       Impact factor: 4.226

Review 4.  Chromatin remodeling in mammary gland differentiation and breast tumorigenesis.

Authors:  Tim H-M Huang; Manel Esteller
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-07-07       Impact factor: 10.005

Review 5.  Prostate cancer epigenome.

Authors:  Swathi Chinaranagari; Pankaj Sharma; Nathan J Bowen; Jaideep Chaudhary
Journal:  Methods Mol Biol       Date:  2015

6.  In utero life and epigenetic predisposition for disease.

Authors:  Kent L Thornburg; Jackilen Shannon; Philippe Thuillier; Mitchell S Turker
Journal:  Adv Genet       Date:  2010       Impact factor: 1.944

Review 7.  CD133: to be or not to be, is this the real question?

Authors:  Elena Irollo; Giuseppe Pirozzi
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

8.  HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.

Authors:  Cassandra A Godman; Rashmi Joshi; Brendan R Tierney; Emily Greenspan; Theodore P Rasmussen; Hsin-Wei Wang; Dong-Guk Shin; Daniel W Rosenberg; Charles Giardina
Journal:  Cancer Biol Ther       Date:  2008-10-07       Impact factor: 4.742

9.  Hyperactivated NF-{kappa}B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells.

Authors:  'Matladi N Ndlovu; Carine Van Lint; Karlien Van Wesemael; Pieter Callebert; Dany Chalbos; Guy Haegeman; Wim Vanden Berghe
Journal:  Mol Cell Biol       Date:  2009-08-17       Impact factor: 4.272

10.  Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.

Authors:  Daisy Corvetta; Olesya Chayka; Samuele Gherardi; Cosimo W D'Acunto; Sandra Cantilena; Emanuele Valli; Izabela Piotrowska; Giovanni Perini; Arturo Sala
Journal:  J Biol Chem       Date:  2013-01-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.